Navigation Links
Salix Pharmaceuticals Previews Digestive Disease Week 2007

f C. difficile strain Z. Jiang, M.D. May 20 isolated from patients with hospital- associated diarrhea The effect of selective intestinal A. Saveriadis, M.D. May 20 decontamination on liver hemodynamics in patients with alcohol related decompensated cirrhosis Restless leg syndrome in patients with L. Weinstock, M.D. May 21 irritable bowel disease: response to bacterial overgrowth therapy Small intestinal bacterial overgrowth in L. Weinstock, M.D. May 21 patients with interstitial cystitis and gastrointestinal symptoms Double blind, randomized study to M. Lukas, M.D. May 22 evaluate efficacy and urinary excretional rate of two doses of rifaximin-EIR in mild to moderate active Crohn's disease (GRACE 02 study) Rifaximin as a steroid-sparing T. Shah, M.D. May 23 medication in the management of patients with mild to moderate inflammatory bowel disease Decreasing rates of colectomy despite M. Issa, M.D. May 23 high rates of hospitalization in C. difficile infected IBD patients: a tertiary referral center experience MOVIPREP Better efficacy of a new 2-liter bowel L. Clark May 22 cleansing preparation in the ascending colon Randomised and controlled clinical trial H. Gruss May 23 of polyethylene glycol with electrolytes and ascorbic acid in comparison to sodium phosphate for bowel preparation before colon cancer screening colonoscopy COLAZAL Efficacy and safety of balsalazide for J. Quiros May 22 treatment of pediatric patients with mild to moderate ulcerative colitis: A randomized double-blind study

CONTINUING MEDICAL EDUCATION ACTIVITES

In addition, Salix is supporting, through an unrestricted educational grant, two continuing medical education activities in conjunction with DDW this year: -0-

"Navigating the
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Salix Pharmaceuticals Previews Digestive Disease Week
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Germany, April 25, 2007-Labtec GmbH (Langenfeld,Germany), a ... multiple dose clinical study for their proprietary,Sufentanil ... to announce the successful,completion of the second ... for this program was to complete this ...
... At Least 10 Genetic Variants Are Associated,With Adult ... – In the most,comprehensive look at genetic risk ... team, working in close collaboration with two,other groups, ... with increased risk of diabetes and confirmed existence,of ...
Cached Medicine Technology:Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7
(Date:8/2/2015)... , ... August 03, 2015 , ... ... will be attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) ... , “We are pleased for the opportunity the AHDI conference provides us to ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... 2015 , ... For many “would be” entrepreneurs, starting a new business can prove to ... to start a business.” Neither needs be a major obstacle. , The U.S. has ... a business and be successful. The risks of starting a business can be high but ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/2/2015)... ... 02, 2015 , ... Molecular biologists in New South Wales say a protein ... has just posted an article on the new research. Click here to read ... Ki67 expression in tissue samples from 42 patients with peritoneal mesothelioma and found a ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 Senetek ... engaged in the development of technologies that target the ... quarter and year ended December 31, 2008. Revenue for ... with $26,471,000 reported in 2007. Revenues for the ...
... 31 The following is a statement by Lois ... Senate Majority Leader Smith and Assembly Speaker Silver for ... benefit under one of New York,s most beneficial programs ... program was in danger of losing more than $50 ...
... CITY, Mo., March 31 DST Systems, Inc. (NYSE: ... 50% of Argus Health Systems, Inc. ("Argus"). Argus is now ... in this press release may include forward-looking statements respecting DST ... DST,s views as of today, and actual actions or results ...
... DIEGO, March 31 - Orexigen(R) Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... as President and Chief Executive Officer of the ... M.D., Executive Chairman and Interim President and CEO. ...
... JACKSONVILLE, Fla., March 31 MSC ... products and services to post-discharge and post-injury workers, ... acquired Optimal Translation & Transportation, a national company ... acquisition further fortifies MSC,s position in the market, ...
... 31, 2009 -- Scientists who first established a link ... live in the intestine now are investigating whether the ... Researchers at Washington University School of Medicine in St. ... whether severely malnourished infants living in Malawi and Bangladesh ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: